A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Forman, Stephen J., M.D., F.A.C.P. Bookmark and Share

Laboratory of Stephen J. Forman, M.D., F.A.C.P.

Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies.  For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that frequently has acquired resistance to conventional treatment modalities.

A conceptually attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets.  Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in antitumor immunity.  Technologies are now available for identifying T-cell target epitopes expressed by human tumors, isolating T cells for genetic modification to recognize these tumor targets, and then expanding these cells ex vivo to large numbers for reinfusion.  Initial clinical trials for lymphoma, leukemia and malignant glioma employing adoptive transfer of tumor-specific T cells have commenced at City of Hope.
 
T Cell Therapeutics Research Laboratory Members:
 
Christine Brown, Ph.D.
Associate Research Professor
Associate Director of TCTRL
cbrown@coh.org
626-256-HOPE (4673),ext. 63977

Elizabeth Budde, M.D., Ph.D.
Assistant Research Professor
Staff Physician
ebudde@coh.org
626-256-HOPE (4673),ext. 62407
 
Monique Dao, Ph.D.
Assistant Research Professor
mdao@coh.org
626-256-HOPE (4673),ext. 89317
 
Marissa Del Real, Ph.D.
Postdoctoral Fellow
mdelreal@coh.org
626-256-HOPE (4673),ext. 81962
 
Julie Ostberg, Ph.D.
Assistant Research Professor
Scientific Writer
Lab Research Regulatory Coordinator
jostberg@coh.org
626-256-HOPE (4673),ext. 65249
 
Saul Priceman, Ph.D.
Assistant Research Professor
spriceman@coh.org
626-256-HOPE (4673),ext. 64508
 
Sandra Thomas, Ph.D.
Staff Scientist
Scientific Writer
sthomas@coh.org
626-256-HOPE (4673),ext. 64182
 
Xiuli Wang, M.D., Ph.D.
Associate Research Professor
xiuwang@coh.org
626-256-HOPE (4673),ext. 63511
 
Lihong Weng, M.D.
Staff Scientist
lweng@coh.org
626-256-HOPE (4673),ext. 89060
 
Jingying Xu, Ph.D.
Staff Scientist
jixu@coh.org
626-256-HOPE (4673),ext. 63478
 
Brenda Aguilar, B.S.
Senior Research Associate
Animal Studies Supervisor
baguilar@coh.org
626-256-HOPE (4673),ext. 63927
 
Alfonso Brito, M.S.
Research Associate II
abrito@coh.org
626-256-HOPE (4673),ext. 63804
 
Wen Chung Chang, M.S.
Staff Scientist
Molecular Studies Supervisor
wchang@coh.org
626-256-HOPE (4673),ext. 64155

Brenda Chang, B.S.
Research Associate II
bchang@coh.org
626-256-HOPE (4673),ext. 63274
 
Ethan Gerdts, B.S.
Research Associate I
egerdts@coh.org
626-256-HOPE (4673),ext. 62153
 
Martha Gonzalez
Senior Administrative Support
mgonzalez@coh.org
626-256-HOPE (4673),ext. 60201
 
Rochelle Hernandez, B.S.
Research Associate II
rochernandez@coh.org
626-256-HOPE (4673),ext. 81962
 
Anita Kurien, MBS
Regulatory Affairs Specialist I
akurien@coh.org
626-256-HOPE (4673),ext. 60242
 
Araceli Naranjo, B.A.
Staff Scientist
Cell Manufacturing Supervisor
anaranjo@coh.org
626-256-HOPE (4673),ext. 64181
 
Adam Norris, B.S.
Clinical Research Coordinator II
anorris@coh.org
626-256-HOPE (4673),ext. 62312
 
Alina Oancea, M.D., M.S.
Research Associate II
aoancea@coh.org
626-256-HOPE (4673),ext. 64533
 
Anthony Park, M.S.
Intern
apark@coh.org
626-256-HOPE (4673),ext. 62153
 
Alexandra Pike
Trainee
apike@coh.org
626-256-HOPE (4673),ext. 62153
 
Lauren Quezada, M.S.
Research Associate II
lquezada@coh.org
626-256-HOPE (4673),ext. 64533
 
Aniee Sarkissian, M.S.
Research Associate II
asarkissian@coh.org
626-256-HOPE (4673),ext. 63927
 
Jennifer Simpson, B.A.
Clinical Research Coordinator III
jsimpson@coh.org
626-256-HOPE (4673),ext. 65087
 
Renate Starr, M.S.
Senior Research Associate
TCTRL Lab Manager
rstarr@coh.org
626-256-HOPE (4673),ext. 63274
 
Ellie Taus, B.S.
Research Associate I
etaus@coh.org
626-256-HOPE (4673),ext. 81937
 
Ryan Urak, M.S.
Research Associate II
rurak@coh.org
626-256-HOPE (4673),ext. 81937
 
Leonor Velasco
Research Lab Technician
lvelasco@coh.org
626-256-HOPE (4673),ext. 64184
 
Jamie Wagner, B.A.
Regulatory Affairs Specialist III
Clinical Research Regulatory Coordinator
jwagner@coh.org
626-256-HOPE (4673),ext. 60056
 
Laurelin Wolfenden, B.S.
Research Associate I
lwolfenden@coh.org
626-256-HOPE (4673),ext. 64533

Winnie Wong, B.S.
Senior Research Associate
wiwong@coh.org
626-256-HOPE (4673),ext. 81937
 
Sarah Wright, B.S.
Research Associate I
sawright@coh.org
626-256-HOPE (4673),ext. 63804
 
Yubo Zhai, B.S.
Research Associate I
yzhai@coh.org
626-256-HOPE (4673),ext. 89060

Stephen J. Forman, M.D., F.A.C.P. Research

Adoptive Immunotherapy
Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies. For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that often has acquired resistance to conventional treatment modalities. An attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets. Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in anti-tumor immunity. This has led to our overall interest in using adoptive immunotherapy of T-cells to target cancer, specifically leukemia/lymphoma, brain tumors and neuroblastoma. Areas of focus in our research program are outlined below.
 
Glioma tumor cells are killed by therapeutic T-cells
Scanning of zetakine redirected cytolytic T-cell lysis of a glioma tumor cell.
 
Genetic Modification of T-cells for Redirected Tumor Recognition
Technologies are now available for identifying immunogenic T-cell target epitopes expressed by human tumors, isolating antigen-specific T-cells and expanding them ex vivo to large numbers for reinfusion. However, to overcome the difficulties of isolating tumor-reactive T-cells from cancer patients, we have developed technology to take T-cells from a cancer patient and reprogram them to target a patient’s cancer through genetic engineering strategies using DNA electroporation and/or lentiviral transduction. Previous studies by our laboratory have provided proof of principle that CTL can be engineered to specifically target lymphoma, neuroblastoma, and glioma tumors via expression of tumor-specific chimeric immunoreceptors resulting in MHC-independent killing of target tumor cells (Cooper et al, Blood 2003; Park et al, Mol Therapy 2007; Kahlon et al, Cancer Res 2004). More recently, we have completed pre-clinical studies of cytotoxic T-cells (CTLs) genetically modified to express an IL13-zetakine chimeric immunoreceptor to target cell-surface IL13Rα2 on medulloblastoma/primitive neuroectodermal tumors, the most common type of brain tumor in children (Stastny et al, J Ped Hematol Oncol 2007). Overall, we are currently involved in studying the potential clinical utility of adoptively transferring T-cells that have been genetically redirected to recognize CD19 (on leukemia and lymphoma); IL13Ra2 (on glioblastoma and medulloblastoma); L1-CAM (on neuroblastoma, lung cancer, and renal cell carcinoma); HER2 (on breast cancer, brain metastases and medulloblastoma); or alpha-3 integrin (on medulloblastoma).
 
 
Murine Xenograft ModelsSurgical suite
To monitor the therapeutic objectives of adoptive T-cell transfer before entering the clinical setting, our lab has developed multiple murine xenograft models. For example, we are now routinely performing stereotactic surgeries in mice for the intracranial injection of human brain tumors to mimic the situation of our patients. In addition, we have also developed lymphoma, neuroblastoma, and medulloblastoma murine xenograft models. Bioluminescent strategies have also been developed by our group for the in vivo imaging of both T-cells and tumors. Our utilization of the firefly and renilla luciferase genes (ffLuc and rLuc, respectively) along with the Xenogen system for serial imaging of anesthetized mice has been critically important for evaluating our animal studies. Specifically, these animal model systems are being used for studying the efficacy of immunotherapy, T-cell trafficking from tail vein injections, contralateral homing of T-cells to tumors within the parenchyma of the brain, and studies of T-cell persistence and proliferation.
 
Trafficking of Adoptively Transferred T-cells
To exert a therapeutic effect, adoptively transferred tumor-specific cytotoxic T-cells (CTLs) must traffic to sites of tumor burden, exit the circulation, and infiltrate the tumor microenvironment. T-cells are able to respond to migration directing chemicals, called chemokines, that are produced by tumor cells. Thus our group has begun to examine the ability of adoptively transferred human CTLs to traffic to tumors. Using a combination of in vivo tumor tropism studies, and in vitro biophotonic chemotaxis assays, we observed that tumors that produce CCL2/MCP1 (>10ng/ml), such as cell lines derived from glioma and medulloblastoma, efficiently chemoattract ex vivo expanded primary human T-cells. These studies suggest that the capacity of adoptively transferred T-cells to home to tumors may be influenced in part by the species and amounts of tumor-derived chemokines, in particular MCP-1 (Brown et al, J Immunol 2007).
 
Targeting Tumor Progenit or Cells with Genetically Engineered Effector T-Cells
Recent hypotheses that tumors arise from cancer stem cells which appear to be resistant to radiation treatment and chemotherapy have also led us to begin to isolate and expand stem cells from human glioma to assess the vulnerability of these cells to T-cell mediated killing in our adoptive immunotherapy models. Our initial studies demonstrate that chimeric immunoreceptor redirected IL13Rα2-specific CTL, currently being evaluated in an FDA-approved pilot Phase I trial for the treatment of recurrent/refractory malignant glioma, can kill cancer stem/progenitor cells in vitro, and reduce engrafted potential of the glioma stem/progenitor population in an orthotopic murine tumor model. Current models now predict that curative therapies for many cancers might require the elimination of the stem/progenitor population, and these studies lay the foundation for an immunotherapy approach to achieve this goal.
 
Development of Strategies to Optimize T-cell Anti-Tumor Activity in Vivo
Our group has also begun to investigate the expression of additional gene products in T-cells that may serve to overcome constraints on T-cell effector function and survival in vivo. For example, we are currently examining the efficacy of providing co-stimulatory signaling to T-cells through integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor.  Our recent studies in this area demonstrate that integrating costimulation with activation signaling events is important for fully activating CD4+ anti-tumor effector cells, resulting in sustained function in the tumor microenvironment.
 
Another strategy we are currently examining is the utility of genetically modifying T-cells which have first been selected for specificity to viruses such as CMV or EBV, which would allow for endogenous stimulation of these T-cells upon their transfer to patients infected with these viruses that are frequently reactivated in infected hosts. We would also predict that such a combinatorial bispecific T-cell strategy would permit the selective isolation of virus specific memory T-cells as recipients of chimeric antigen receptor genes for improved in vivo persistence following adoptive transfer. In fact, studies on the unique engraftment potential of memory T-cells are also being carried out in primates in collaboration with Dr. Berger at the Fred Hutchison Cancer Research Center in Seattle, WA. Because tumors can avoid immune-mediated elimination by production of immunosuppressive cytokines (e.g., TGF-b), our group is also evaluating strategies by which T-cells may be rendered resistant to such immunosupression. One project is the development of interference RNA sequences that could decrease this susceptibility of T-cells to tumor-mediated suppression. In collaboration with Sangamo Biosciences in Richmond, CA, we are also interested in studying the effects of genetically blocking glucocorticoid sensitivity of the tumor specific T-cells because post-operative brain cancer patients are routinely treated with immunosuppressive steroids (i.e., glucocorticoids) to reduce clinical symptoms of edema.
 
Lastly, another group of projects underway in the lab are examining ways of generating gene products that influence the expression of cytokines such as IL-2 and IL-7 which help promote the survival of T-cells and are critical for generating T-cell memory responses. A new collaboration with Dr. Smolke in the Chemical Engineering Department at CalTech involves the development of RNA regulating systems that are inducible by drugs such as tetracycline to control the expression of cytokines in T-cells which will promote their proliferation and survival.
 
Overall, the recent progress and current directions of Dr. Forman’s research group have generated much enthusiasm and support at City of Hope. The laboratory and office space in the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology is located in the heart of City of Hope. This state-of-the-art center is dedicated to immunotherapy and facilitates collaboration between lab researchers and clinicians, and rapidly moves scientific discoveries from the lab to patients.
 
 

Forman, Stephen J., M.D., F.A.C.P.

Laboratory of Stephen J. Forman, M.D., F.A.C.P.

Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies.  For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that frequently has acquired resistance to conventional treatment modalities.

A conceptually attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets.  Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in antitumor immunity.  Technologies are now available for identifying T-cell target epitopes expressed by human tumors, isolating T cells for genetic modification to recognize these tumor targets, and then expanding these cells ex vivo to large numbers for reinfusion.  Initial clinical trials for lymphoma, leukemia and malignant glioma employing adoptive transfer of tumor-specific T cells have commenced at City of Hope.
 
T Cell Therapeutics Research Laboratory Members:
 
Christine Brown, Ph.D.
Associate Research Professor
Associate Director of TCTRL
cbrown@coh.org
626-256-HOPE (4673),ext. 63977

Elizabeth Budde, M.D., Ph.D.
Assistant Research Professor
Staff Physician
ebudde@coh.org
626-256-HOPE (4673),ext. 62407
 
Monique Dao, Ph.D.
Assistant Research Professor
mdao@coh.org
626-256-HOPE (4673),ext. 89317
 
Marissa Del Real, Ph.D.
Postdoctoral Fellow
mdelreal@coh.org
626-256-HOPE (4673),ext. 81962
 
Julie Ostberg, Ph.D.
Assistant Research Professor
Scientific Writer
Lab Research Regulatory Coordinator
jostberg@coh.org
626-256-HOPE (4673),ext. 65249
 
Saul Priceman, Ph.D.
Assistant Research Professor
spriceman@coh.org
626-256-HOPE (4673),ext. 64508
 
Sandra Thomas, Ph.D.
Staff Scientist
Scientific Writer
sthomas@coh.org
626-256-HOPE (4673),ext. 64182
 
Xiuli Wang, M.D., Ph.D.
Associate Research Professor
xiuwang@coh.org
626-256-HOPE (4673),ext. 63511
 
Lihong Weng, M.D.
Staff Scientist
lweng@coh.org
626-256-HOPE (4673),ext. 89060
 
Jingying Xu, Ph.D.
Staff Scientist
jixu@coh.org
626-256-HOPE (4673),ext. 63478
 
Brenda Aguilar, B.S.
Senior Research Associate
Animal Studies Supervisor
baguilar@coh.org
626-256-HOPE (4673),ext. 63927
 
Alfonso Brito, M.S.
Research Associate II
abrito@coh.org
626-256-HOPE (4673),ext. 63804
 
Wen Chung Chang, M.S.
Staff Scientist
Molecular Studies Supervisor
wchang@coh.org
626-256-HOPE (4673),ext. 64155

Brenda Chang, B.S.
Research Associate II
bchang@coh.org
626-256-HOPE (4673),ext. 63274
 
Ethan Gerdts, B.S.
Research Associate I
egerdts@coh.org
626-256-HOPE (4673),ext. 62153
 
Martha Gonzalez
Senior Administrative Support
mgonzalez@coh.org
626-256-HOPE (4673),ext. 60201
 
Rochelle Hernandez, B.S.
Research Associate II
rochernandez@coh.org
626-256-HOPE (4673),ext. 81962
 
Anita Kurien, MBS
Regulatory Affairs Specialist I
akurien@coh.org
626-256-HOPE (4673),ext. 60242
 
Araceli Naranjo, B.A.
Staff Scientist
Cell Manufacturing Supervisor
anaranjo@coh.org
626-256-HOPE (4673),ext. 64181
 
Adam Norris, B.S.
Clinical Research Coordinator II
anorris@coh.org
626-256-HOPE (4673),ext. 62312
 
Alina Oancea, M.D., M.S.
Research Associate II
aoancea@coh.org
626-256-HOPE (4673),ext. 64533
 
Anthony Park, M.S.
Intern
apark@coh.org
626-256-HOPE (4673),ext. 62153
 
Alexandra Pike
Trainee
apike@coh.org
626-256-HOPE (4673),ext. 62153
 
Lauren Quezada, M.S.
Research Associate II
lquezada@coh.org
626-256-HOPE (4673),ext. 64533
 
Aniee Sarkissian, M.S.
Research Associate II
asarkissian@coh.org
626-256-HOPE (4673),ext. 63927
 
Jennifer Simpson, B.A.
Clinical Research Coordinator III
jsimpson@coh.org
626-256-HOPE (4673),ext. 65087
 
Renate Starr, M.S.
Senior Research Associate
TCTRL Lab Manager
rstarr@coh.org
626-256-HOPE (4673),ext. 63274
 
Ellie Taus, B.S.
Research Associate I
etaus@coh.org
626-256-HOPE (4673),ext. 81937
 
Ryan Urak, M.S.
Research Associate II
rurak@coh.org
626-256-HOPE (4673),ext. 81937
 
Leonor Velasco
Research Lab Technician
lvelasco@coh.org
626-256-HOPE (4673),ext. 64184
 
Jamie Wagner, B.A.
Regulatory Affairs Specialist III
Clinical Research Regulatory Coordinator
jwagner@coh.org
626-256-HOPE (4673),ext. 60056
 
Laurelin Wolfenden, B.S.
Research Associate I
lwolfenden@coh.org
626-256-HOPE (4673),ext. 64533

Winnie Wong, B.S.
Senior Research Associate
wiwong@coh.org
626-256-HOPE (4673),ext. 81937
 
Sarah Wright, B.S.
Research Associate I
sawright@coh.org
626-256-HOPE (4673),ext. 63804
 
Yubo Zhai, B.S.
Research Associate I
yzhai@coh.org
626-256-HOPE (4673),ext. 89060

Research

Stephen J. Forman, M.D., F.A.C.P. Research

Adoptive Immunotherapy
Advances in surgery, radiation therapy and chemotherapy over the last decade have increased the cure rates of a variety of malignancies. For patients whose tumors are not eradicated, however, the impediment most frequently encountered is the inability to fully eliminate the minimal residual disease that often has acquired resistance to conventional treatment modalities. An attractive strategy for targeting minimal residual disease is the manipulation of immunologic effector cells to specifically recognize tumor targets. Animal models and an increasing number of clinical trials have implicated the T lymphocyte as a pivotal immunologic effector cell in anti-tumor immunity. This has led to our overall interest in using adoptive immunotherapy of T-cells to target cancer, specifically leukemia/lymphoma, brain tumors and neuroblastoma. Areas of focus in our research program are outlined below.
 
Glioma tumor cells are killed by therapeutic T-cells
Scanning of zetakine redirected cytolytic T-cell lysis of a glioma tumor cell.
 
Genetic Modification of T-cells for Redirected Tumor Recognition
Technologies are now available for identifying immunogenic T-cell target epitopes expressed by human tumors, isolating antigen-specific T-cells and expanding them ex vivo to large numbers for reinfusion. However, to overcome the difficulties of isolating tumor-reactive T-cells from cancer patients, we have developed technology to take T-cells from a cancer patient and reprogram them to target a patient’s cancer through genetic engineering strategies using DNA electroporation and/or lentiviral transduction. Previous studies by our laboratory have provided proof of principle that CTL can be engineered to specifically target lymphoma, neuroblastoma, and glioma tumors via expression of tumor-specific chimeric immunoreceptors resulting in MHC-independent killing of target tumor cells (Cooper et al, Blood 2003; Park et al, Mol Therapy 2007; Kahlon et al, Cancer Res 2004). More recently, we have completed pre-clinical studies of cytotoxic T-cells (CTLs) genetically modified to express an IL13-zetakine chimeric immunoreceptor to target cell-surface IL13Rα2 on medulloblastoma/primitive neuroectodermal tumors, the most common type of brain tumor in children (Stastny et al, J Ped Hematol Oncol 2007). Overall, we are currently involved in studying the potential clinical utility of adoptively transferring T-cells that have been genetically redirected to recognize CD19 (on leukemia and lymphoma); IL13Ra2 (on glioblastoma and medulloblastoma); L1-CAM (on neuroblastoma, lung cancer, and renal cell carcinoma); HER2 (on breast cancer, brain metastases and medulloblastoma); or alpha-3 integrin (on medulloblastoma).
 
 
Murine Xenograft ModelsSurgical suite
To monitor the therapeutic objectives of adoptive T-cell transfer before entering the clinical setting, our lab has developed multiple murine xenograft models. For example, we are now routinely performing stereotactic surgeries in mice for the intracranial injection of human brain tumors to mimic the situation of our patients. In addition, we have also developed lymphoma, neuroblastoma, and medulloblastoma murine xenograft models. Bioluminescent strategies have also been developed by our group for the in vivo imaging of both T-cells and tumors. Our utilization of the firefly and renilla luciferase genes (ffLuc and rLuc, respectively) along with the Xenogen system for serial imaging of anesthetized mice has been critically important for evaluating our animal studies. Specifically, these animal model systems are being used for studying the efficacy of immunotherapy, T-cell trafficking from tail vein injections, contralateral homing of T-cells to tumors within the parenchyma of the brain, and studies of T-cell persistence and proliferation.
 
Trafficking of Adoptively Transferred T-cells
To exert a therapeutic effect, adoptively transferred tumor-specific cytotoxic T-cells (CTLs) must traffic to sites of tumor burden, exit the circulation, and infiltrate the tumor microenvironment. T-cells are able to respond to migration directing chemicals, called chemokines, that are produced by tumor cells. Thus our group has begun to examine the ability of adoptively transferred human CTLs to traffic to tumors. Using a combination of in vivo tumor tropism studies, and in vitro biophotonic chemotaxis assays, we observed that tumors that produce CCL2/MCP1 (>10ng/ml), such as cell lines derived from glioma and medulloblastoma, efficiently chemoattract ex vivo expanded primary human T-cells. These studies suggest that the capacity of adoptively transferred T-cells to home to tumors may be influenced in part by the species and amounts of tumor-derived chemokines, in particular MCP-1 (Brown et al, J Immunol 2007).
 
Targeting Tumor Progenit or Cells with Genetically Engineered Effector T-Cells
Recent hypotheses that tumors arise from cancer stem cells which appear to be resistant to radiation treatment and chemotherapy have also led us to begin to isolate and expand stem cells from human glioma to assess the vulnerability of these cells to T-cell mediated killing in our adoptive immunotherapy models. Our initial studies demonstrate that chimeric immunoreceptor redirected IL13Rα2-specific CTL, currently being evaluated in an FDA-approved pilot Phase I trial for the treatment of recurrent/refractory malignant glioma, can kill cancer stem/progenitor cells in vitro, and reduce engrafted potential of the glioma stem/progenitor population in an orthotopic murine tumor model. Current models now predict that curative therapies for many cancers might require the elimination of the stem/progenitor population, and these studies lay the foundation for an immunotherapy approach to achieve this goal.
 
Development of Strategies to Optimize T-cell Anti-Tumor Activity in Vivo
Our group has also begun to investigate the expression of additional gene products in T-cells that may serve to overcome constraints on T-cell effector function and survival in vivo. For example, we are currently examining the efficacy of providing co-stimulatory signaling to T-cells through integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor.  Our recent studies in this area demonstrate that integrating costimulation with activation signaling events is important for fully activating CD4+ anti-tumor effector cells, resulting in sustained function in the tumor microenvironment.
 
Another strategy we are currently examining is the utility of genetically modifying T-cells which have first been selected for specificity to viruses such as CMV or EBV, which would allow for endogenous stimulation of these T-cells upon their transfer to patients infected with these viruses that are frequently reactivated in infected hosts. We would also predict that such a combinatorial bispecific T-cell strategy would permit the selective isolation of virus specific memory T-cells as recipients of chimeric antigen receptor genes for improved in vivo persistence following adoptive transfer. In fact, studies on the unique engraftment potential of memory T-cells are also being carried out in primates in collaboration with Dr. Berger at the Fred Hutchison Cancer Research Center in Seattle, WA. Because tumors can avoid immune-mediated elimination by production of immunosuppressive cytokines (e.g., TGF-b), our group is also evaluating strategies by which T-cells may be rendered resistant to such immunosupression. One project is the development of interference RNA sequences that could decrease this susceptibility of T-cells to tumor-mediated suppression. In collaboration with Sangamo Biosciences in Richmond, CA, we are also interested in studying the effects of genetically blocking glucocorticoid sensitivity of the tumor specific T-cells because post-operative brain cancer patients are routinely treated with immunosuppressive steroids (i.e., glucocorticoids) to reduce clinical symptoms of edema.
 
Lastly, another group of projects underway in the lab are examining ways of generating gene products that influence the expression of cytokines such as IL-2 and IL-7 which help promote the survival of T-cells and are critical for generating T-cell memory responses. A new collaboration with Dr. Smolke in the Chemical Engineering Department at CalTech involves the development of RNA regulating systems that are inducible by drugs such as tetracycline to control the expression of cytokines in T-cells which will promote their proliferation and survival.
 
Overall, the recent progress and current directions of Dr. Forman’s research group have generated much enthusiasm and support at City of Hope. The laboratory and office space in the Arnold and Mabel Beckman Center for Cancer Immunotherapeutics & Tumor Immunology is located in the heart of City of Hope. This state-of-the-art center is dedicated to immunotherapy and facilitates collaboration between lab researchers and clinicians, and rapidly moves scientific discoveries from the lab to patients.
 
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • Patients undergoing treatment at City of Hope know they will be receiving the best medical care available, that their treatment will be delivered with compassion and that their care will extend to their families. “When we treat a patient here, we treat a family,” says Jo Ann S. Namm, child life manager and spec...
  • Did you know that colorectal cancer equally affects men and women? Or that it’s the third-leading cause of cancer death in the U.S.? Most important, did you know that colorectal cancer is very treatable and highly curable if detected early? If you didn’t know these facts, it’s time to learn. M...
  • To celebrate the beginning of Lunar New  Year 2015, City of Hope honored not just a new lunar calendar, but also the diversity of the community it serves. On Jan. 21, as tens of thousands of people celebrated Lunar New Year (and the arrival of the Year of the Ram) in the streets of L.A.’s Chinatown, City of [&#...
  • The breakthroughs that have revolutionized cancer treatment, transforming cancer in many cases to a very manageable and even curable disease, started out as just ideas. “I will often tell patients there’s no therapy we’re using to help them that wasn’t derived from somebody’s idea in some laboratory, working la...
  • The prostate cancer screening debate, at least as it relates to regular assessment of prostate specific antigen levels, is far from over. The U.S. Preventive Services Task Force recommended against routine PSA screening for prostate cancer in 2012, maintaining that the routine use of the PSA blood test does mor...
  • Cancer patients should get more than medical treatment. They should get comprehensive, evidence-based care that addresses their full range of needs. That kind of patient-focused care is City of Hope’s specialty. Under the guidance of Dawn Gross, M.D., Ph.D., the new Arthur M. Coppola Family Chair in Suppo...
  • Think twice before tossing out those hormone replacement pills. Although a new Lancet study suggests that hormone replacement therapy could increase a woman’s risk of ovarian cancer, a City of Hope expert urges women to keep this news in perspective. Hormone replacement therapy is prescribed to help allev...
  • Don’t know what to take, or send, that friend of yours in the hospital? Try a paper plate — filled not with cookies or sweets, but an image of yourself. Ilana Massi, currently undergoing treatment at City of Hope for acute myeloid leukemia, can vouch for the power of such a gift. She’s surrounded herself [̷...
  • With precision medicine now a national priority, City of Hope has joined a novel research partnership designed to further understanding of cancer at the molecular level, ultimately leading to more targeted cancer treatments. The Oncology Research Information Exchange Network, or ORIEN, is the world’s larg...
  • The spinal cord is an integral part of the human body, connecting the brain to everything else. So when a tumor grows on the spine, any messages that the brain tries to send to the rest of the body are interrupted, making everyday tasks — such as walking — more difficult. This year an estimated 22,850 […]
  • Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor’s stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 perc...
  • Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, offers his perspective on the benefits of surgery for aggressive prostate cancer. For men walking out of the doctor’s office after a diagnosis of cancer, the reality can hit like a ton of bricks. Th...
  • Although many Hispanic women face a high risk of mutations in the BRCA1 and BRCA2 genes – increasing their risk of breast and ovarian cancer – screenings for these mutations can be prohibitively expensive in Mexico and other Latin American countries. As a result, too many women don’t get the information t...
  • Providing lung cancer treatments to patients when their cancer is at its earliest and most treatable stages will now be a more attainable goal: Medicare has agreed to cover lung cancer screening for those beneficiaries who meet the requirements. The only proven way to detect lung cancer early enough to save liv...
  • At City of Hope, innovative scientific research, important clinical studies and vital construction projects are all powered by philanthropy. Generous supporters fuel a powerful and diverse range of progress in science and medicine, enabling researchers and clinicians to improve cancer treatments and create cure...